Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith S Currier

Showing results (241-250 of 298) with videos related to

Pageof 30
Sort By:
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
HIV Clinical Trials|March 21, 2019
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trialRisa M Hoffman, Konstantia Nadia Angelidou, Sean S Brummel, et al.
Journal of the American Heart Association|December 11, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVEAya Awwad, Christopher de Filippi, Heather Ribaudo, et al.
The Lancet. HIV|June 7, 2025
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysisCarl J Fichtenbaum, Carlos D Malvestutto, Maya G Watanabe, et al.
Circulation. Heart Failure|December 29, 2025
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Gerald S Bloomfield, Maya Watanabe, Sara McCallum, et al.
The Lancet. HIV|January 20, 2025
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVESteven K Grinspoon, Markella V Zanni, Virginia A Triant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
AIDS (London, England)|May 27, 2025
Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trialChristopher deFilippi, Aya Awwad, Gerald S Bloomfield, et al.
AIDS (London, England)|June 18, 2025
No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIVKristine M Erlandson, Ashley McKhann, Douglas W Kitch, et al.
The Lancet. HIV|April 3, 2025
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trialMarissa R Diggs, Triin Umbleja, Sara McCallum, et al.
Pageof 30

Showing results (241-250 of 298) with videos related to

Sort By:
Pageof 30
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
HIV Clinical Trials|March 21, 2019
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trialRisa M Hoffman, Konstantia Nadia Angelidou, Sean S Brummel, et al.
Journal of the American Heart Association|December 11, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVEAya Awwad, Christopher de Filippi, Heather Ribaudo, et al.
The Lancet. HIV|June 7, 2025
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysisCarl J Fichtenbaum, Carlos D Malvestutto, Maya G Watanabe, et al.
Circulation. Heart Failure|December 29, 2025
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Gerald S Bloomfield, Maya Watanabe, Sara McCallum, et al.
The Lancet. HIV|January 20, 2025
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVESteven K Grinspoon, Markella V Zanni, Virginia A Triant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
AIDS (London, England)|May 27, 2025
Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trialChristopher deFilippi, Aya Awwad, Gerald S Bloomfield, et al.
AIDS (London, England)|June 18, 2025
No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIVKristine M Erlandson, Ashley McKhann, Douglas W Kitch, et al.
The Lancet. HIV|April 3, 2025
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trialMarissa R Diggs, Triin Umbleja, Sara McCallum, et al.
Pageof 30